Faeth Therapeutics (FTH) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$3.91
- EPS estimate
- −$5.60
- EPS surprise
- +30.18%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 5, 2025
The most recent quarter in Faeth Therapeutics' table is Q2 2025, reported August 5, 2025. The company posted a loss of $3.91 per share, narrower than the expected loss of $5.60, a beat of 30.18%. A year earlier, in Q2 2024, the loss was $5.60 per share, so the loss was about 30% smaller. The table gives no revenue figures or revenue estimates for any quarter.
Every quarter in the table is a loss. Full-year losses were $27.20 per share in 2021, $31.60 in 2022, $24.40 in 2023 and $24.00 in 2024. The largest quarterly loss shown was $20.90 in Q4 2020. Since then, quarterly losses have ranged from $3.91 to $8.80, and Q2 2025's was the smallest of all. The first half of 2025 lost $9.31 per share, against $12.00 a year earlier. Results came in better than estimates in 11 of the 19 quarters shown.
The table holds no results after Q2 2025, although past Q3 reports came in early to mid November and Q4 reports between late February and late March. Until newer quarters appear in the data, this summary covers only the period through mid-2025, and the next report in the table will be Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 5, 2025 | −$5.60 | −$3.91 | +30.18% | $0.00 | SEC |
| Q1 2025 | May 6, 2025 | −$4.47 | −$5.40 | −20.89% | $0.00 | SEC |
| Q4 2024 | Mar 28, 2025 | −$5.67 | −$6.20 | −9.41% | $0.00 | SEC |
| Q3 2024 | Nov 14, 2024 | −$6.24 | −$5.80 | +7.00% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$5.77 | −$5.60 | +2.95% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$5.50 | −$6.40 | −16.37% | $0.00 | SEC |
| Q4 2023 | Feb 28, 2024 | −$6.15 | −$6.00 | +2.48% | $0.00 | SEC |
| Q3 2023 | Nov 7, 2023 | −$6.78 | −$5.60 | +17.43% | $0.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$6.61 | −$6.20 | +6.20% | $0.00 | SEC |
| Q1 2023 | May 9, 2023 | −$7.12 | −$6.60 | +7.25% | $0.00 | SEC |
| Q4 2022 | Mar 28, 2023 | −$8.00 | −$8.00 | +0.02% | $0.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$7.40 | −$8.80 | −18.92% | $0.00 | SEC |
| Q2 2022 | Aug 9, 2022 | −$7.90 | −$6.80 | +13.92% | $0.00 | SEC |
| Q1 2022 | May 10, 2022 | −$7.00 | −$8.00 | −14.29% | $0.00 | SEC |
| Q4 2021 | Mar 10, 2022 | −$6.80 | −$6.00 | +11.76% | $0.00 | SEC |
| Q3 2021 | Nov 9, 2021 | −$4.90 | −$6.40 | −30.61% | $0.00 | SEC |
| Q2 2021 | Aug 4, 2021 | −$5.81 | −$6.40 | −10.19% | $0.00 | SEC |
| Q1 2021 | May 12, 2021 | −$8.41 | −$8.40 | +0.13% | $0.00 | SEC |
| Q4 2020 | Mar 25, 2021 | −$6.33 | −$20.90 | −230.18% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Faeth Therapeutics (FTH) last report earnings?
Faeth Therapeutics last reported on Aug 5, 2025, covering fiscal Q2 2025.
Did FTH beat earnings estimates?
Yes. Faeth Therapeutics reported EPS of −$3.91 for Q2 2025 against a −$5.60 estimate — a 30.18% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.